BioNTech SE (BNTX) Cash from Financing Activities (2018 - 2025)

BioNTech SE has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$16.6 million for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at -$16.6 million, down 113.39% year-over-year; the trailing twelve-month figure through Dec 2025 was -$59.7 million (down 20.26% YoY), and the FY2025 annual result was -$59.8 million, down 21.85% from the prior year.
• Cash from Financing Activities came in at -$16.6 million for Q4 2025 at BioNTech SE, down from -$13.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $184.1 million in Q2 2021 to a low of -$833.9 million in Q2 2022.
• The 5-year median for Cash from Financing Activities is -$14.2 million (2023), against an average of -$111.9 million.
• Peak annual rise in Cash from Financing Activities reached 1560.33% in 2022, while the deepest fall reached 118001159.55% in 2022.
• BioNTech SE's Cash from Financing Activities stood at $55.94 in 2021, then slumped by 118001159.55% to -$66.0 million in 2022, then soared by 78.97% to -$13.9 million in 2023, then jumped by 43.8% to -$7.8 million in 2024, then sank by 113.39% to -$16.6 million in 2025.
• The last three Cash from Financing Activities figures came in at -$16.6 million (Q4 2025), -$13.4 million (Q3 2025), and -$15.1 million (Q2 2025), per Business Quant data.